We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Crowdfunding Opportunities by Envestors


AgPlus has created a diagnostic platform for detecting human diseases and delivering laboratory instrument results instantly, whilst keeping in mind the business requirements and unmet requirements. The company works in collaboration with leading diagnostics companies to improve and share products quickly and globally. It aims is to become known as a leader in Point of Care diagnosis.
investment: £905,005 target: £1,600,000
status: Active 4 days
to go

Platform:
Envestors

More Information
57% of Funding Target Achieved
Fizzbox is an online marketplace created to sell and organise group booking. This platform also offers customers benefits like free cancellation and booking with just 20% deposit. The company's website has a mission to become the world's largest event company that does not organize events. The company has completed over 1,626 bookings that resulted in £79,000 of commission and £478,000 of revenues in the first year of trading. With the proceeds, the company will complete application development, marketing, recruitment, and fund general working capital.
investment: Unknown target: £1,000,000
status: Active 19 days
to go

Platform:
Envestors

More Information
Warwick Acoustics produces Electrostatic Audio Systems for the auto industry. The company is partnered with various car Original Equipment Manufacturers and Tier 1 suppliers to produce and distribute automotive solutions. 
investment: Unknown target: £5,500,000
status: Active 19 days
to go

Platform:
Envestors

More Information
Adande Aircell®Limited (AAL) is an airflow management system designed to fit into the current cabinet designs to minimise and reduce energy usage, improve temperature stability, and stop cold air falling out. It significantly improves the efficiency and performance of the refrigerator. The Aircell® technology is protected by a bunch of series of patents filed internationally and in the UK. With the proceeds, the company will manufacture and sell the whole unit and create a secondary stream to ensure that the company can demonstrate the technology through trade shows and in-store demonstrations.
investment: Unknown target: £1,500,000
status: Active 11 days
to go

Platform:
Envestors

More Information
HotelSwaps is the world’s leading hotel room swap programme that enables owners of independent hotels to swap unused hotel rooms using HotelCoins®. It a technology platform with 420+ active users. It has established partnerships with hotels such as Relais & Chateaux, SiteMinder and Design Hotels. The company 465 hotels members in 64 countries.
investment: Unknown target: £1,000,000
status: Active 19 days
to go

Platform:
Envestors

More Information
Living With is a health technology company offering a pocket-friendly and simple patient management application that allows medical professionals treat and track patients remotely. The app aims to revolutionise the way doctors and hospitals access digital tools to treat patients while collecting data for medical device and pharma companies. The company owns Squeezy (a popular paid medical app in the UK) and already has five products in 17 NHS Trusts. Living With also has a contract with one of the world’s greatest medical device companies. Living With will use the proceeds to give 5 data (drug/device) and 50 access customers (clinic/doctor), become HIPAA compliant for the US and to quicken sales and marketing.
investment: £55,000 target: £400,000
status: Active 50 days
to go

Platform:
Envestors

More Information
14% of Funding Target Achieved
Antev Limited (Antev) is a clinical-stage biopharmaceutical firm which focuses on the evolution of a drug used for prostate cancer, Teverelix TFA. The company is working on growing its copyright protection and is currently developing phase IIb clinical plans for prostate cancer. Antev is a pre-revenue company that aims at increasing its shareholder value by progressing the development of teverelix TFA towards registration whose approval is anticipated from 2023 onwards. The proceeds will be used for production, IP development, working capital and to develop a phase IIb repeat dosing clinical trial in prostate cancer.
investment: Unknown target: £2,000,000
status: Active 110 days
to go

Platform:
Envestors

More Information
Art, Analysis and Research is a leading scientific art testing company which provides art authenticity and attribution reports. The company has created a suite of state-of-the-art imaging systems, materials testing and data analytics to analyse and authenticate art. Art, Analysis and Research has offices in the two major art centres of New York and London along with market-leading mobile solution. Its customer base includes major auction houses, museums, dealers and artist foundations. The funds will be used to boost sales and marketing to meet the growing market demand.
investment: Unknown target: £1,500,000
status: Active 110 days
to go

Platform:
Envestors

More Information
Ablatus Therapeutics is a MedTech company developing a one-of-a-kind tissue ablation platform known as Bimodal Electric Tissue Ablation (BETA). This technology has been designed to overcome the limitations of existing products by offering ablation solutions in oncology (tumours) as well as non-oncology targets. With the proceeds, the company will finish the final elements of engineering of the generator and probe. It will also deliver formal safety test data that is a prerequisite for subsequent clinical trials.
investment: £600,000 target: £1,500,000
status: Active 110 days
to go

Platform:
Envestors

More Information
40% of Funding Target Achieved
EarlyBird have created a number of different healthy snack packs, all made with fresh ingredients. EarlyBird deliver their snacks straight to your door meaning you don't have to leave the comfort of your home. 
investment: £168,000 target: £750,000
22% of Funding Target Achieved
Ombar is re-defining chocolate by making premium chocolate bars from unroasted raw cacao and other natural, healthy ingredients.
investment: £354,000 target: £1,000,000
35% of Funding Target Achieved
EnXray have patented and developed a low-energy x-ray technology which allows medical instruments to be sterilised at source and cuts out the need for them to be sent to a third party for sterilisation before returning to the manufacturer for distribution to doctors and hospitals.    
investment: £375,000 target: £500,000
75% of Funding Target Achieved
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph